| Document |
Document Title |
|
WO/2022/134033A1 |
Provided are methods of preparing heteroaryl-ketone fused azadecal in glucocorticoid receptor modulators, and compositions having low impurity levels.
|
|
WO/2022/126888A1 |
The present invention provides a compound having a pancreatic islet protection function, and a preparation method therefor and an application thereof. The structural formula (I) of the compound is shown as follows. The present invention ...
|
|
WO/2022/127779A1 |
Provided in the present invention are a substituted pyridazinone compound and the use thereof. The substituted pyridazinone compound is a compound represented by general formula I, or a pharmaceutically acceptable salt, a prodrug, a hydr...
|
|
WO/2022/127699A1 |
The present invention relates to a thyroid hormone receptor β selective agonist compound represented by general formula I, a pharmaceutical composition and use thereof. The compound improves the selectivity of THR-α and the druggabilit...
|
|
WO/2022/124311A1 |
[Problem] The purpose of the present invention is to provide an agent capable of enhancing the female hormone-like action of equol. [Solution] The effect of enhancing the female hormone-like action of equol is exhibited as a result of us...
|
|
WO/2022/117696A1 |
The present invention relates to the use of a composition comprising a progesterone derived from a tree of the genus Juglans to induce ovulation in a livestock mammal selected from among the ruminant and monogastric mammals.
|
|
WO/2022/117778A1 |
The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid ...
|
|
WO/2022/116382A1 |
A human glucagon-like peptide-1 receptor (GLP-1R) activator, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, and R6 are each independently selected from any one of H, C1-C4 al...
|
|
WO/2022/116693A1 |
The present invention relates to a GLP-1R receptor agonist compound and a use thereof. Specifically, the present invention discloses a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound can be...
|
|
WO/2022/115417A1 |
Disclosed herein are NLRP3 inflammasome inhibitors and compositions thereof. Also disclosed herein are methods including administering a therapeutically effective amount of a composition comprising at least one NLRP3 inflammasome inhibit...
|
|
WO/2022/114105A1 |
The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity β-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass% or higher and in...
|
|
WO/2022/111581A1 |
A benzazepine spiro derivative as represented by formula (I) and a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/109684A1 |
A dosage form for oral delivery of a therapeutic agent to a subject, the dosage form comprising: (i) a lipid nanocarrier formulation, the lipid nanocarrier formulation comprising the therapeutic agent, and lipids in the form of a mesopha...
|
|
WO/2022/106557A1 |
The present invention relates to a compound having general formula I for use in the activation of AMPK. A composition comprising said compound and methods for use thereof, in the activation of AMPK, are also provided.
|
|
WO/2022/106712A1 |
The subject matter of the invention relates to a tetrapeptide which binds to the ZIP9 receptor for the treatment of osteoporosis, myodegenerative diseases, and male infertility. The invention also relates to the use of the tetrapeptide a...
|
|
WO/2022/106566A1 |
Object of the present invention is an improved process for the preparation of Trenbolone Acetate of formula (I) having irregular hexagon plates crystal habit and/or a median value (D50) of the particle size distribution comprised in the ...
|
|
WO/2022/104413A1 |
Provided herein are compositions, methods and kits for effectively preventing, treating, reducing, mitigating, or controlling female sexual interest and arousal disorder (FSIAD), wherein the method comprises administering to a subject in...
|
|
WO/2022/105041A1 |
Provided is an application of an miR-325 nucleic acid analog in the preparation of a related product for treating sinusoidal endothelial cell pathological dysfunction. By directly or indirectly affecting signal pathways by means of miR-3...
|
|
WO/2022/101495A1 |
The disclosure provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 ...
|
|
WO/2022/101303A1 |
This disclosure relates to combined oral preparations of N-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-diox
o-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-m
ethoxyurea (Compound 1), a...
|
|
WO/2022/104394A1 |
Systems and methods to assess insulin resistance are described. Further, compounds and methods for treatment of insulin resistance or hyperglycemia are described. In some instances, immunoglobins of an individual are utilized in an insul...
|
|
WO/2022/099049A1 |
Disclosed herein are methods of modulating the activity of a thyroid hormone receptor beta and methods of treating disease using a pyridazinone compound.
|
|
WO/2022/093714A1 |
The disclosure provides, inter alia, methods to treat hypertension in patients using CYP 11 β2 beta hydroxylase inhibitors.
|
|
WO/2022/089591A1 |
The application of glucosamine in the preparation of drugs for the treatment of non-alcoholic fatty liver disease and diabetes. Experiments have proven that glucosamine at a daily dose of 300-600 mg/kg can improve insulin resistance, gly...
|
|
WO/2022/087658A1 |
The present invention generally relates to modulating insulin expression and production by targeting CD47. In a particular aspect, the invention relates increasing insulin expression by silencing or blocking CD47. In another aspect, the ...
|
|
WO/2022/092294A1 |
The present disclosure has solved problems associated with the TGF-β family or the like, which is called Myostatin/GDF-8 as a molecular mechanism and targeted by sarcopenia, by evaluating a pharmaceutical product in physiological aging ...
|
|
WO/2022/087141A1 |
The disclosure describes a method of preparing pyridazinone derivatives comprising contacting a compound of formula (I) or a salt thereof: (I) with a compound of formula (II) or a salt thereof: (II) to form a compound of formula (III) or...
|
|
WO/2022/084752A1 |
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...
|
|
WO/2021/048195A9 |
This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevent...
|
|
WO/2022/075436A1 |
The present invention aims at improving the stability of a thyroid hormone-containing solid formulation. More specifically, the present invention aims at developing a technique capable of further improving the stability of a thyroid horm...
|
|
WO/2022/076385A1 |
Methods of attenuating an antigenic response in a mammal to one or more Type 1 diabetes related-antigens are provided. The method may result in delaying the onset of decreased pancreatic beta cell function in the mammal and/or at least d...
|
|
WO/2022/073649A1 |
The present invention relates to alpha/beta hydrolase variants with improved properties compared to a parent alpha/beta hydrolase, e.g., having increased temperature stability, methods of using and producing such variants including metho...
|
|
WO/2022/071484A1 |
The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...
|
|
WO/2022/068918A1 |
An application of an acid-base neutralization combination as a topical active ingredient in the preparation of a topical medicine for the treatment of local pathological diseases, a topical pharmaceutical composition comprising same, and...
|
|
WO/2022/069956A1 |
An orodispersible formulation for contraception or hormone replacement therapy containing an estrogen and a progestogen that has sufficient hardness, disintegration time and friability.
|
|
WO/2022/068924A1 |
Provided in the present invention are a new use of a probiotic component and a topical pharmaceutical composition containing the probiotic component, and the use of the probiotic component as an active ingredient that can provide a thera...
|
|
WO/2022/068915A1 |
Provided are a 6-oxo-1,6-dihydropyridazin derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a 6-oxo-1,6-dihydropyridazin derivative as shown by general formu...
|
|
WO/2022/071334A1 |
The present invention provides a means for producing a parathyroid gland organoid. A culture method according to the present invention includes: a cell mass containing parathyroid gland cells at a content ratio of 50% or more and mesench...
|
|
WO/2022/067602A1 |
A crystal of a thyroid hormone ß receptor agonist, a preparation method therefor and use thereof. The crystal has substantially no hygroscopicity, and has a smaller crystal particle size and a larger drug specific surface area, so that ...
|
|
WO/2022/064035A1 |
The present invention relates to a sustained-release PTH compound for use in a method of improving and treating the physical and mental well-being of patients having hypoparathyroidism, wherein the sustained-release PTH compound releases...
|
|
WO/2022/057845A1 |
Provided are a compound serving as a thyroid hormone β receptor agonist and uses of the compound, also provided is a pharmaceutical composition comprising the compound. The compound or the pharmaceutical composition is applicable in pre...
|
|
WO/2022/058951A1 |
The present invention relates to luteinising hormone (LH) or to a molecule having LH-like activity or to a composition comprising it for use in inducing the activation, and/or the maturation of primordial and/or primary follicles in an i...
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/057157A1 |
A traditional Chinese medicine composition for treating precocious puberty in children, and a preparation method therefor and the use thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by...
|
|
WO/2022/052822A1 |
The present invention relates to a new crystal form of Resmetirom (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition comprising the crystal from, and a use of the crystal form in preparing a THR...
|
|
WO/2022/052454A1 |
The use of an ester group-containing aromatic propionamide compound in the preparation of a medicine for treating dry eye syndrome.
|
|
WO/2022/055880A1 |
A spray-dried solid dispersion comprising: (a) 3 - [4 -(4 -amino -piperidin-I-y l)-3 -(3,5 -difluoro-phenyI)- quinolin-6 -yl] -2 -hydroxy-benzonitrile, or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically ...
|
|
WO/2022/047543A1 |
An intramedullary device for transplanting cells into a medullary cavity of a bone having an elongate shaft defining an internal lumen and a perforated region. The device further includes a semipermeable immuno-isolation housing within t...
|
|
WO/2022/047517A1 |
The present disclosure relates to methods for preparing derivatives of peptides and proteins, including preparing sialyl- glycosylated peptides and proteins, and to the resulting derivatives of peptides and proteins and their uses. The d...
|
|
WO/2022/049168A1 |
The present invention relates to the use of 17(S)-HDPA against metabolic syndrome related diseases including NAFLD/NASH.
|
